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Introduction. The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines,
remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and
platelet-rich plasma (PRP) for the treatment of BRONJ in cancer patients. Methods. We performed a longitudinal cohort study.
Inclusion criteria were (1) age ≥ 18 years; (2) cancer diagnosis; (3) treatment with NBP because of the underlying cancer. Results.
We consecutively recruited ten patients diagnosed with BRONJ in stage I or II. These patients underwent a surgical laser-assisted
therapy together with autologous PRP. At the latest follow-up at 12 months, clinical improvement was observed in eight patients.
Registration Number is IRCT20180329039159N1. Conclusion. We could successfully manage the BRONJ utilizing this combined
protocol to heal the 30% of surgically treated sites and to improve the 50% of patients’ lesions clinically. Our findings suggest that
a surgical approach combined with Er,Cr:YSGG laser and PRP benefit cancer patients with general health issues.
1. Introduction
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is
a severe adverse reaction of bisphosphonates (BPs) treatment;
it is a relative rare but potentially serious, painful, and
debilitating complication that can significantly affect the
quality of life of cancer patients [1, 2].
The optimal treatment of BRONJ remains controversial;
but the main objectives in the treatment are to control
infection, to slow the disease’s progression, and to promote
tissue healing [1–4].
The BRONJ treatments are classified into surgical and
non-surgical options. The non-surgical treatments include
the use of systemic antibiotic therapy and oral antiseptic
rinses, variably combined with hyperbaric oxygen therapy,
low-level laser therapy, and medical ozone applications [5–
9]. The surgical treatments proposed in the literature are
divided into conservative approaches such as bone debride-
ment, sequestrectomy, or more aggressive therapies such as
resections of affected bone and jawbone reconstruction, if
indicated [4, 10–12].
In the past, the surgical treatments were reserved only for
advanced stages of BRONJ; the Italian Society of Oral and
Maxillofacial Surgery (SICMF) and the Italian Society of Oral
Pathology and Medicine (SIPMO) in 2012 recommended
conservative surgery in lesions belonging to stages I and II,
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as defined by both societies, that can provide resolution of
acute infection and offers long-term of well-being for patients
[10, 11, 13–17].
A few clinical studies utilizing Er,Cr:YSGG laser-assisted
conservative surgery have showed promising results in
BRONJ treatment [6, 10, 15, 18].
Utilizing the Er,Cr:YSGG laser, during the necrotic tissue
removal, eliminates thermal effect in cutting areas and sur-
rounding tissues and provides antibacterial and biostimula-
tive effects to reduce post-operative pain and promotes the
tissue healing.The laser acts through a cutting effect in a “con-
tact free” way and avoids any friction, which normally delays
the healing’s process and causes the thermal and mechanical
trauma. It applies microfractures and microexplosions to
remove themineralized tissue and vaporize water to allow the
rapid removal of the tissue layers that saves bone surface from
any contaminations. The Er,Cr:YSGG laser, in particular,
owns all these features, allowing a complete healing for both
soft and hard tissues [19–23].
Autologous platelet concentrates, such as platelet-rich
plasma (PRP), are increasingly applied as a new approach to
regenerate tissues in oral surgery as they release high quanti-
ties of growth factors, including platelet-derived growth fac-
tor (PDGF), vascular endothelial growth factors (VEGF), and
transforming growth factor-b (TGF-b) [24–27]. PDGF plays
a role in healing hard and soft tissues by stimulating mito-
genesis, chemotaxis, and producing fibronectin. High VEGF
in wound sockets improves the formation of bone matrix
and stimulates the neoangiogenesis. TGF-b stimulates the
fibroblast chemotaxis and produces fibronectin and collagen
to repair connective tissues and regenerate bones [28–30].
Indeed, PRP accelerates epithelial wound healing, decreases
tissue inflammation, improves the regeneration of bone and
soft tissues, and promotes tissue vascularization. Considering
these benefits, PRP would be effective in BRONJ patients in
the way that releases growth factors and stimulates the bone
healing and neoangiogenesis, which is usually suppressed by
BPs [26, 31–37]. Moreover, PRP as an autologous product
possesses biocompatibility and safety.
This study aimed to evaluate the effect on clinical healing
of a combined treatment consisting of laser-assisted surgery
and PRP in cancer patients affected by BRONJ.
2. Patients and Methods
2.1. Study Design. We performed a prospective cohort study
on consecutive cancer patients followed at the Unit of Oral
Medicine of theUniversityHospital “P.Giaccone” of Palermo.
The Institutional Local Ethics Committee of the University
Hospital “P.Giaccone” of Palermo approved the study in 2015.
Technical and surgical procedures were done in accor-
dance with the Declaration of Helsinki revised in 2000.
(Table 1). All participants signed the informed consent.
2.2. Entry and Exclusion Criteria. BRONJ was defined as
exposed or non-exposed osteonecrosis of the mandible or
maxilla [2]. Patients were eligible for the study if they had
(1) age ≥ 18 years; (2) cancer; (3) treatment with BPs because
of the underlying cancer. Patients were excluded from the
Table 1: Technical procedures.
Step Procedure
1 Clinical Evaluation
2
Computer Tomography (CT) evaluation
Lesions’ classification following SIPMO-SICMF staging
system Scaling (when required) and oral hygiene
instructions
Pre-operatory medical therapy prescription (Table 2)
Platelet rich-plasma (PRP) preparation
3
Surgical procedure (Figure 1)
Er,Cr:YSGG Laser surgery
PRP application
Flap suture
4 Suture removal and clinical control
5 Follow-up visits at 15 days, one month, three, six, twelve
months
study if they had (1): previous history of irradiation to the
maxillofacial area; (2) neoplastic involvement of the jaws;
(3) previous surgical treatment to the jaws; (4) poor general
conditions.
We diagnosed BRONJ in all cases through a clinical-
radiological approach combining clinical examination and
Computed Tomography (CT) of the affected jaws. A radi-
ologist with experience and a special interest in head and
neck imaging assessed and reported CT scan, while the local
clinical team was in charge of the final diagnosis.
2.3. Clinical Examination. At first visit, we collected the
clinical, drug, and dental history of patients, which consisted
of the following: (1) age; (2) sex; (3) reason for BPs usage;
(4) BPs type; (5) duration of BPs treatment; (6) cumulative
dose of BPs; (7) concurrent use of steroids; (8) history of
chemotherapy; (9) concurrent use of antiangiogenics; (10)
concomitant diseases; (11) risk factors for BRONJ (e.g. history
of diabetes); (12) clinical features of BRONJ; and (13) patients’
habits (e.g. smoking and oral hygiene). We classified lesions
following SICMF-SIPMO clinical and radiological staging
system of BRONJ [2, 5].
2.4. Surgical Treatment. All patients underwent periopera-
tive pharmacological treatment based on the administration
of ampicillin and sulbactam (pre-operative regimens: 1g
i.m. 2xdaily starting 1 day pre-operatively; post-operative
regimens: 1g i.m. 2xdaily for 7 days) and metronidazole
(pre-operative regimens: 500mg per os 3xdaily starting 1
day pre-operatively; post-operative regimens: 500mg per os
3xdaily for 7 days). The use of antiseptic (chlorhexidine
0,2% mouthwashes 30ml swished up to 60 seconds, 3x daily
7 days pre-operatively and 15 days post-operatively) and
sodium-hyaluronate (local application 3x daily 10 days post-
operatively) was also prescribed (Table 2); autologous PRP
(Plateltex ACT System, Biomed, Modena, IT) and surgical
therapy were then prepared. To prepare the PRP and to
induce its gelation, the materials provided by the manufac-
turer were used and the provided instructions followed [38].
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Table 2: Prescribed medical therapy to enrolled patients.
Operatory medical therapy
Pre-
Ampicillin and sulbactam: 1g i.m. 2xdaily starting 1 day before. Metronidazole: 500mg per os 3x
daily starting 1 day before.
Chlorexidine 0,2% mouthwashes 30 ml swished up to 60 seconds, 3x daily 7 days before.
Post-
Ampicillin and sulbactam: 1g i.m. 2xdaily for 7 days. Metronidazole: 500mg per os 3x daily for 7
days.
Chlorhexidine 0,2% mouthwashes 30 ml swished up to 60 seconds, 3x daily 15 days post-
operatively.
Local application of Sodium-hyaluronate 3xdaily 10 days post-operatively.
All surgical procedures were performed under local
anesthesia using 3% mepivacaine hydrochloride without
adrenaline.
The surgical protocol consisted of elevation of a full-
thickness mucoperiosteal flap to expose the surgical area;
bony curettage (debridement) and sequestrectomy of the
necrotic bone, whether required, using a Er,Cr:YSGG laser
(Waterlase MD, Biolase Technology, San Clemente, CA,
USA); application of autologous PRP; tension-free soft tissue
closure (Figure 1).
The Er,Cr:YSGG laser permits photons with wavelength
of 2.78𝜇m and a pulsed duration of 140-200 microseconds
with a repetition rate of 20Hz. The laser device uses a pulsed
energy source; a sapphire MS75 tip (Biolase, Inc.) with a
length of 6mm and diameter of 750𝜇m was used with an
80%water and 40% air spray during irradiation. The sapphire
tip was positioned 1 to 2mm from the target tissue and was
kept perpendicular to the irradiated bone surface. The power
output of the laser can be varied from0 to 6W,while the beam
spot size at the tip was 1.26⋅10 3mm2.
2.5. Follow-Up. We scheduled follow-up visits to remove the
suture seven days after surgery and visited patients on the
fifteenth day, and the visits were continued on months one,
three, six, and twelve (Figures 2-3).
We performed Computer Tomography (CT) scans for all
patients preoperatively and at the 12-month follow-up (T
1
) to
restage the disease.
2.6. Main Outcome. We defined successful treatment as the
absence of clinical and radiological signs of BRONJ relapse
(healing) or, in turn, the transition from a higher stage to a
lower one (improvement).
2.7. Statistical Analysis. Statistical units are the patients who
satisfy the inclusion criteria of the study. Descriptive statistic
was carried out. We summarized continuous variables with
means and standard deviations and computed categorical
variables frequencies distributions. We analyzed qualitative
variables, staging and bone status, and compared them at
baseline (T0) and after the treatment (T1). We applied the
Wilcoxon signed-rank test with continuity correction for
BRONJ staging.We analyzed all data using R software version
3.3.2. A p-value less than 0.05 was considered statistically
significant.
3. Results
3.1. Patients’ Features. During the study period, ten cancer
patients completed the protocol and were available for the
analysis. They were mostly females (70%), with a mean age
75,2 ± 5,94 years. Multiple myeloma was the most common
diagnosis (40%), followed by breast (30%) and prostate
cancer (30%).
All patients but one had been on monthly infusions
of zoledronic acid (mean duration: 31,8 ± 25,76 months);
this latter was shifted from zoledronic acid to ibandronic
acid during treatment. Two patients (20%) were on sys-
temic corticosteroid therapy and five had been exposed to
chemotherapy; only one patient received both steroids and
chemotherapy (Table 3).
Mandible was the most frequent site of BRONJ (90%).
Eight patients showed frank bone exposure at the first
visit (80%), while 20% did not and were classified as non-
exposed BRONJ cases, based on the presence of oral pain and
radiological signs of bone necrosis.
At baseline (T
0
), six patients were classified in stage IB
(60%), two in stage IIA (20%), and the remaining two in stage
IIB (20%) (Table 3), according to the SICMF-SIPMO clinical
and radiological staging system of BRONJ [2].
3.2. Main Outcome. The wound healing was completed at
the time of suture removal in 30% of patients. At the latest
follow-up period (T
1
), we observed a clinical improvement in
80% of patients after surgical therapy that was confirmed by
Wilcoxon test (p-value = 0.01187). In particular, six patients
showed non-exposed bone (60%). Among them, three (30%)
had no clinical and radiological signs of BRONJ (complete
healing). Five patients showed a clinical improvement of
symptoms (50%), while 2 did not show clinical improvement
(20%). These latter had been preoperatively classified in
stage IIA. Overall, at T
1
four patients were in stage IA
(40%) and three patients in IIA (30%). Results are shown in
Table 4.
4. Discussion
We succeeded to manage BRONJ patients performing the
conservative surgery treatment through Er,Cr:YSGG laser
combined PRP, both able to enhance the bone and mucosal
healing, with a successful outcome of 80% (30% patients with
4 BioMed Research International
(a) (b)
(c) (d)
Figure 1: (a) Preoperative clinical view; (b) sutures; (c) postoperative view after sequestrectomy procedures; (d) bone fragment.
(a) (b)
(c) (d)
Figure 2: (a) Clinical view after 7 days; (b) after 1 month; (c) after 6 months; (d) after 12 months.
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Figure 3: Radiologic outcome at 12 months’ follow-up, CT scan slices.
no clinical and radiological signs of BRONJ relapse and 50%
with clinical improvement).
The use of laser technology for BRONJ treatment and
its beneficial effects on tissue healing has been widely inves-
tigated in the last years. Many authors suggested the com-
bination of low-level laser therapy (LLLT) with traditional
surgical approach, to biostimulate the tissues healing [6, 39–
41].
The use of Er,Cr:YSGG laser has a great potential in
the hard tissues surgery; indeed Er,Cr:YSGG laser enables
efficient resection of the maxilla without using conventional
rotary instruments, as the laser produces a clear and precise
cut with minimal injury to contiguous hard and soft tissues
[6, 20, 23, 42, 43].
This device showed good results in conservative surgery
approach of BRONJ treatment in different stages. Vescovi
et al. reported several studies regarding the use of Er:YAG
laser to treat BRONJ lesions, showing that Er:YAG seems to
represent a high percentage of success, with significantly bet-
ter results compared with the traditional surgical approaches
[15, 39, 44, 45].
Many authors suggested the application of PRP to
improve postsurgical wound healing. PRP gel stimulates the
release of growth factors and promotes angiogenesis and
bone and mucosal healing. In addition, PRP is autologous,
biocompatible, and safe product [24–27, 29].
The properties of autologous platelet concentrates appear
particularly useful in BRONJ surgical therapy, as the lack
of vascularization represents one of the major factors on
pathogenesis of BRONJ.
Coviello et al. reported a case series with seven patients
taking BPs and affected by BRONJ referable to tooth extrac-
tion. They treated four of BRONJ patients by standard
surgical debridement and sequestrectomy, while applying
supplementary autologous PRP in the three. The authors
observed wound healing’s improvement and bone exposure
reduction in the PRP group [46].
Martins et al. also studied the association of laser pho-
totherapy (LPT) and PRP on healing outcome of BRONJ
in cancer patients. These authors retrospectively compared
the effects on wound healing of this protocol with a non-
surgical (pharmacological therapy) and a surgical (pharma-
cological plus surgical therapy) one. They obtained higher
rates of success, in terms of mucosal wound healing, in
patients surgically treated with the LPT plus PRP protocol
[47].
Longo et al. also achieved good results by studying
the therapeutic effects in surgery therapy associated with
PRP to promote BRONJ wounds healing [48]; performing
a comparison with a surgical approach without PRP. They
present higher success rate among patients treated with PRP
(PRP group 93% of complete response versus control group
53% of complete response).
Lately, Kim et al. reported the application of leucocyte-
rich and platelet-rich fibrin (L-PRF) in the treatment of
BRONJ, with a complete resolution in 77% of cases treated
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Table 3: Descriptive statistics of the 10 enrolled patients.
Age (years) 75,2±5,94
Sex
Male 3 (30%)
Female 7 (70%)
Smokers 2 (20%)
Cancer
Multiple Myeloma 4 (40%)
Breast cancer 3 (30%)
Prostate cancer 3 (30%)
Comorbidities
Diabetes 2 (20%)
Hypertensions 6 (60%)
Corticosteroids 2 (20%)
Osteoporosis 5 (50%)
Chemotherapy 5 (50%)
Rheumatoid arthritis 1 (10%)
Involved bone
Maxilla 1 (10%)
Mandible 9 (90%)
BRONJ stage∗
I A 0
I B 6 (60%)
II A 2 (20%)
II B 2 (20%)
Bone exposure
Yes 8 (80%)
No 2 (20%)
Intravenous Bisphosphonates treatment time (mo) 31,8±25,76
∗ BRONJ stage according to SICMF-SIPMO clinical and radiological staging system.
and a delayed resolution in 18% of cases [49]. Comparing
these results with ours, the success percentages are almost
similar.
Notably, Mozzati et al. described the treatment of 32
BRONJ cases all belonging to stage IIB with the application
of plasma rich in growth factors (PRGF) and reported a
success rate of 100% with only temporary postoperative
complications[24]. In 2017, also Maluf et al. reported two
cases of medication related ONJ (classifiable as stage II)
completely healed after a surgical treatment combined with
the application of L-PRF[50].
Del Fabbro et al., in their systematic review, illustrated the
data about fourteen studies published between 2007 and 2014;
the BRONJ surgical treatment with an adjunct autologous
platelet concentrates showed a satisfactory healing in 91,6% of
the cases [36]. All these data are in agreement with our results
in the treatment of BRONJ stage IIB.
Our study’s limitations include the limited sample
size and the presence of confounding factors, such as
applied comedications (e.g. corticosteroids and/or different
chemotherapy) in some patients. Indeed, these drugs could
inhibit cell proliferation and with an antiangiogenic action
could suppress vascular endothelial growth factor (VEGF)
and fibroblast growth factor (FGF) [51–53].
5. Conclusion
Despite progress in the prevention of BRONJ, a specific
treatment protocol to manage BRONJ is still missing.
Surgical removal of the necrotic bone should be per-
formed with the Er,Cr:YSGG laser, that possesses remark-
able properties with antibacterial and biostimulative effects,
reduce postoperative pain and promote the tissue healing.
Additionaly, PRP is an autologous product, biocompatible,
easy to handle, and rich in growth factors and ameliorates the
tissues healing in residual postsurgical wounds.
More prospective studies are needed to confirm this
statement with a larger patients’ sample. Considering the
limitation of the present study, we could show that conserva-
tive surgical approach with Er,Cr:YSGG laser combined PRP
benefits the management of early stages’ BRONJ in cancer
patients.
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